.png)
GrayMatters Health
FDA-cleared EEG neurofeedback (Prism) for PTSD; IDF-origin, MTEC member
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
GrayMatters Health appears focused on scaling an FDA-cleared, biomarker-driven PTSD and interventional psychiatry platform in the U.S. while maintaining an Israel-based engineering and clinical-development footprint. The company’s direction is consistent with a dual-use adjacent digital therapeutics model that combines evidence generation, clinical adoption, and market expansion through behavioral health clinics.
Efficiency Ratio
The company shows strong innovation output relative to visible public scale, with a comparatively modest corporate footprint but meaningful product and research signals. That suggests an efficient R&D-to-market conversion, though operational breadth appears narrower than that of larger commercial healthtech peers.
Evidence Signals
Website describes Prism for PTSD as a neurofeedback software device and an interventional psychiatry suite powered by proprietary fMRI-informed biomarkers.
Terms of use identify Prism for PTSD as an EEG biofeedback device intended for relaxation and stress reduction, indicating an active marketed product with a defined use case.
MTEC profile states Prism for PTSD is the first FDA-cleared self-neuromodulation device designed to help patients manage PTSD symptoms.
Company states that a growing community of behavioral health clinics across the U.S. is building Prism programs for personalized patient care.
PR Newswire release says GrayMatters Health is expanding patient access of Prism for PTSD across the U.S., implying clinic and distribution partnerships.
LinkedIn lists headquarters in New York and a location in Haifa, Israel, indicating a bi-national operating structure.
PR Newswire cites new research expanding scientific validity and clinical impact of fMRI-informed biomarkers, showing ongoing R&D and publication-oriented activity.
- About
- Israeli digital mental-health company (HQ Haifa, Israel; founded 2016 by Oded Kraft (CEO), Rani Cohen (executive chairman) and Shai Attia), developing self-neuromodulation therapies. Its FDA-cleared flagship Prism is a prescription neurofeedback system — an EEG cap plus software that trains patients to self-regulate an amygdala-derived, fMRI-informed biomarker to control their emotional response, as an adjunctive treatment for PTSD (a depression protocol is in trials). The PTSD biomarker was developed from research on IDF soldiers scanned before and after combat. Prism is in use in US hospitals and Germany, and GrayMatters is a member of the US MTEC (USAMRDC) medical consortium. Opens a warfighter/veteran behavioral-health lane — one of the largest DoD/VA medical demand areas — that the DON medical set otherwise lacks.
- Tags
- #ptsd #neurofeedback #neuromodulation #eeg #behavioralhealth #mentalhealth #veterans #fda #mtec #idforigin #dualuse